Clinical Trial Update: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML [Phase 1]

View source ↗

Summary

A Phase 1 trial of metformin combined with cytarabine for relapsed/refractory acute myeloid leukemia was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia Blast Crisis

Drugs mentioned

• CYTARABINE (CYTARABINE)
• metformin (metformin)

Snippet

Sponsor: Northwestern University | Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Status: TERMINATED | Results posted: 2018-11-13